First-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib (Fukuoka et al., 2011) and erlotinib (Rosell et al., 2012), significantly improve the prognosis of advanced NSCLC patients harboring EGFR-TKI-sensitizing mutations, mainly EGFR Ex19del and L858R, when compared with traditional platinum-based chemotherapy as first-line treatment. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.